# Different Doses of ZED1227 vs. Placebo in NAFLD

> **NCT05305599** · PHASE2 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 186 (actual)

## Conditions studied

- NAFLD
- Liver Fibrosis

## Interventions

- **DRUG:** ZED1227
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05305599
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-19
- **Primary completion:** 2023-06-07
- **Final completion:** 2023-07-05
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05305599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05305599, "Different Doses of ZED1227 vs. Placebo in NAFLD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05305599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*